All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Ophthalmology Product Name: NCX 4251
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
NCX 4251 has first-in-class potential, addressing the unmet medical need of patients with blepharitis. Mississippi Phase 2b trial will evaluate once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Ophthalmology Product Name: NCX 4251
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, was evaluated in the successful Danube Phase 2 trial completed in late 2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Ocumension Therapeutics
Deal Size: $165.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2020
Details:
Nicox will conduct both of its planned Phase 3 clinical trials, Mont Blanc and Denali, as multi-regional clinical trials in U.S. and China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
NCX 470 demonstrated both statistical non-inferiority and superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
Details:
NCX 470 is covered by a composition of matter patent until 2029, which is potentially eligible for up to a 5-year patent term extension based on the period of regulatory review.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
